Assays for hepatitis B surface antigen (HBsAg) are the most frequently ... testing and also to ascertain likely cause of weakly positive (grayzone) results. Results During the 17 month study ...

The report highlighted that testing was conducted for the presence of Hepatitis B surface antigen (HBsAg ... in the number of individuals testing positive for Hepatitis B since 2022.

Interim results from the phase 2b B-Clear showed that bepirovirsen reduced levels of hepatitis B surface antigen (HBsAg) and HBV DNA after 24 weeks' treatment to below the lower limit of detection ...

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta (CHD).

Hepatitis B surface antigen vaccine (recombinant ... of hepatitis B virus to infants born to mothers who are HBsAg positive if vaccination is delayed. Infants Weighing Less Than 2000 g Delay ...

Discover a clinical trial that was conducted to evaluate the efficacy and safety of autologous HBV vaccine-pulsed dendritic cells and their induced T cells.

bepirovirsen at a dose of 300 mg per week over 24 weeks resulted in sustained hepatitis B surface antigen (HBsAg) and HBV DNA loss to below the limits of detection in 9% to 10% of participants ...

A dot plot showing COI for the HBsAg test for all 34 patients who received hepatitis B vaccine 14 days or less before HBsAg testing is shown in Figure 3. There was one patient who had a positive ...